Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
December 02, 2019
1 min read
Save

FDA grants priority review to Imfinzi for lung cancer subset

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to a supplemental biologics license application that seeks approval of durvalumab for previously untreated extensive-stage small cell lung cancer.

Durvalumab (Imfinzi, AstraZeneca) is a human monoclonal antibody that binds to PD-L1. It is approved in the United States for treatment of patients with unresectable stage III non-small cell lung cancer, as well as for previously treated patients with advanced bladder cancer.

The FDA based the new priority review designation on results of the randomized phase 3 CASPIAN trial, which included 805 patients with treatment-naive extensive-stage small cell lung cancer. All patients had WHO performance status of 0 to 1, and those who had asymptomatic or treated and stable brain metastases were eligible.

Researchers assigned patients 1:1:1 to one of three treatment arms: 1,500 mg durvalumab plus chemotherapy for up to four cycles followed by 1,500 mg durvalumab every 4 weeks until disease progression; chemotherapy every 3 weeks for up to six cycles followed by optional prophylactic cranial irradiation; or 1,500 mg durvalumab plus 75 mg tremelimumab (CP-675, AstraZeneca) with chemotherapy every 3 weeks for up to four cycles followed by 1,500 mg durvalumab every 4 weeks until disease progression. Chemotherapy in each arm consisted of 80 mg/m2 to 100 mg/m2 etoposide with either carboplatin area under the curve 5 to 6 or 75 mg/m2 to 80 mg/m2 cisplatin.

OS served as the study’s primary endpoint. Secondary endpoints included PFS, objective response rate, safety and tolerability, and health-related quality of life.

As HemOnc Today previously reported, results showed durvalumab in combination with standard chemotherapy conferred a statistically significant OS benefit (median, 13 months vs. 10.3 months; HR = 0.73; 95% CI, 0.59-0.9). More patients assigned durvalumab survived 1 year (53.7% vs. 39.8%) and 18 months (33.9% vs. 24.7%).